Maryna Kolochavina

Maryna Kolochavina is an experienced professional with 16 years of expertise in lifecycle management for various rare and orphan conditions, particularly in pediatric rare and ultra rare diseases. Her extensive knowledge spans across multiple areas including rare respiratory, ophthalmology, oncology, hematology, neurology, endocrinology, dermatology, gastroenterology, and pediatric diseases.

Maryna's therapeutic class experience covers a wide range of assets, including Antianaemic, Gene therapy, Antiarthritic, Hepatoprotective, Antibody, Hormone, Non-monoclonal antibody, Infection, Anticancer, Metabolic and enzyme disorders, Antidepressant, Monoclonal antibody, Antidiarrhoeal, Muscle relaxant, Antiepileptic, Musculoskeletal, Antifungal, Neurological, Antiinflammatory, Neuroprotective, Antimalarial, Protozoacide, Antithrombotic, Recombinant, Antiulcer, Reformulation, Antiviral, Respiratory, AntiHIV, RNA interference, Blood fraction, Urological, CV, Antisense, Cellular therapy, Antisense therapy, Musculoskeletal, Cystic fibrosis, Diagnostic, Dermatological, and Fusion protein.

In addition to her professional experience, Maryna has a solid educational background having studied at Harvard Business School. She is also associated with various prestigious organizations where she has held key positions, such as Executive Director at Syneos One in Syneos Health (formerly INC Research/inVentiv Health), Sr Director at Syneos Health, Oversight Project Director, Associate Director, MARO at PPD, Senior Project Leader, PACE at Parexel, Global Trial Manager, Clinical Program Leader at Sanofi, and Project Manager, PM Assistant at SPRI Clinical Trials.

Maryna has actively contributed to the industry with over 14 reviews, 25+ presentations, and 30+ publications. She is affiliated with professional organizations like ACRP, BARQA, ASQ, PMI, and serves as a patient advocate at Charité.